Immunoglobulin therapy in Guillain-Barré syndrome in children.
Four children with evolving Guillain-Barré syndrome were treated with a five-day course of intravenous immunoglobulin. No patient showed further progression of the condition and all made a rapid and complete recovery with no evidence of relapse over a six- to 24-month follow-up period. The early use of immunoglobulin in this disorder may prevent further progression of the disease and accelerate short-term recovery, with resulting medical, social and financial implications.
Nicolaides
P
P
Roald Dahl EEG Unit, Royal Liverpool Children's NHS Trust (Alder Hey), Liverpool, UK.
Appleton
R E
RE
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D011129:Polyradiculoneuropathy / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies
D007136:Immunoglobulins